<DOC>
	<DOCNO>NCT02453308</DOCNO>
	<brief_summary>This study open-label randomise trial compare standard ACT treatment match triple artemisinin-based combination therapy ( TACTs ) , evaluate efficacy safety tolerability . The estimated total sample size 2040 patient 16 site Asia 1 site Africa . There 2 arm study group 2 treatment arm . Study group A : A.1 : Artemether-lumefantrine 3 day . versus : A.2 : Artemether-lumefantrine 3 day . plus : Amodiaquine 3 day . Study group B : B.1 : Dihydroartemisinin-piperaquine 3 day . versus : B.2 : Dihydroartemisinin-piperaquine 3 day . plus : Mefloquine hydrochloride 3 day . According WHO guideline , patient except child age 1 year weight 10 kilogram also treat single dose low dose primaquine .</brief_summary>
	<brief_title>A Study Tracking Resistance Artemisinin Collaboration ( TRAC )</brief_title>
	<detailed_description>In Laos , Myanmar , Bangladesh , India DRC , follow two combination use : 1 . Artemether-lumefantrine combined amodiaquine ( TACT arm ) 2 . Artemether-lumefantrine ( ACT arm ) In Cambodia , Myanmar , Vietnam Thailand , follow two combination use : 1 . Dihydroartemisinin-piperaquine combined mefloquine ( TACT arm ) 2 . Dihydroartemisinin-piperaquine ( ACT arm )</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Male female , age 6 month 65 year old Acute uncomplicated P. falciparum malaria , confirm positive blood smear asexual form P. falciparum ( mixed nonfalciparum specie ) Asexual P. falciparum parasitaemia : 5,000 200,000/uL , determine thin thick blood film ( In Cambodia patient parasitaemia 16 200,000/uL eligible . In DRC patient parasitaemia 10,000 250,000/ul eligible ) Fever define &gt; /= 37.5Â°C tympanic temperature history fever within last 24 hour Written inform consent ( parent/guardian case child ) Willingness ability patient parents/guardians comply study protocol duration study Signs severe/complicated malaria Haematocrit &lt; 25 % Hb &lt; 5 g/dL enrollment ( DRC : Hct &lt; 15 % Hb &lt; 5 g/dL due high prevalence anemia ) . Acute illness malaria require treatment For female : pregnancy , breast feeding Patients receive artemisinin derivative artemisinin contain combination therapy ( ACT ) within previous 7 day Treatment mefloquine 2 month prior presentation exclusion criterion DHAP+MQ sit History allergy know contraindication artemisinins , ACT TACT use site e.g . neuropsychiatric disorder contraindication use mefloquine . Previous splenectomy QTcinterval &gt; 450 millisecond moment presentation Documented claimed history cardiac conduction problem Earlier participation within TRACII trial another trial previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Artemisinin combination Therapies</keyword>
</DOC>